Wedbush Securities Inc. bought a new position in shares of Achaogen (NASDAQ:AKAO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,050 shares of the biopharmaceutical company’s stock, valued at approximately $324,000. Wedbush Securities Inc. owned 0.06% of Achaogen at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of AKAO. MetLife Investment Advisors LLC acquired a new stake in shares of Achaogen in the fourth quarter valued at approximately $151,000. Iguana Healthcare Management LLC boosted its position in Achaogen by 150.0% during the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biopharmaceutical company’s stock worth $806,000 after acquiring an additional 45,000 shares during the last quarter. DSC Advisors L.P. acquired a new stake in Achaogen during the fourth quarter worth approximately $752,000. Teachers Advisors LLC boosted its position in Achaogen by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 62,483 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 8,137 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Achaogen during the fourth quarter worth approximately $260,000. Institutional investors own 76.72% of the company’s stock.
In other Achaogen news, major shareholder Robert W. Duggan bought 10,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were acquired at an average price of $10.96 per share, with a total value of $109,600.00. Following the purchase, the insider now owns 5,668,310 shares in the company, valued at approximately $62,124,677.60. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Robert W. Duggan bought 976,880 shares of the business’s stock in a transaction dated Thursday, May 3rd. The stock was acquired at an average cost of $11.33 per share, for a total transaction of $11,068,050.40. Following the purchase, the insider now owns 8,027,627 shares in the company, valued at approximately $90,953,013.91. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 2,555,730 shares of company stock worth $29,790,300 and have sold 10,089 shares worth $110,576. Company insiders own 7.80% of the company’s stock.
NASDAQ:AKAO opened at $12.41 on Tuesday. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of 0.08. The company has a market cap of $524.51 million, a price-to-earnings ratio of -3.91 and a beta of 1.02. Achaogen has a fifty-two week low of $9.83 and a fifty-two week high of $27.49.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.17). The company had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $1.25 million. Achaogen had a negative return on equity of 90.07% and a negative net margin of 2,384.08%. equities analysts predict that Achaogen will post -3.48 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on AKAO. Zacks Investment Research lowered shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. Guggenheim restated a “buy” rating and set a $14.00 target price on shares of Achaogen in a research report on Wednesday, January 10th. HC Wainwright restated a “buy” rating and set a $29.00 target price (up previously from $19.00) on shares of Achaogen in a research report on Monday, April 30th. Mizuho restated a “buy” rating on shares of Achaogen in a research report on Thursday, May 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $20.00 target price (down previously from $29.00) on shares of Achaogen in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. Achaogen currently has an average rating of “Buy” and a consensus price target of $22.67.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Want to see what other hedge funds are holding AKAO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achaogen (NASDAQ:AKAO).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.